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depots. ELP-MCC retained bioactivity against TNFa in vitro with an IC50
2-fold higher than curcumin (24.1mM and 13.5mM, respectively, n¼4).
Following perineural delivery to the sciatic nerve, ELP-MCC displayed
decreased plasma exposure levels compared to curcumin and evidence
of sustained drug release over 96 hrs (Fig 3). Curcumin was completely
cleared from the delivery site after 48 hrs, while low levels of ELP-MCC
remained at the delivery site 96 hrs after delivery.
Conclusions: ELP-MCC conjugates retain activity against TNFa and
provided for sustained release of drug in vivo. These ﬁndings suggest
that ELP may be a suitable carrier for local antagonism of inﬂammation
in back pain. The development of sustained-release drug delivery
systems, such as ELP-MCC, has substantial translational potential for
treating chronic pain and inﬂammation for localized pathologies.
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ASSOCIATIONS BETWEEN STATIN USE AND CHANGES IN PAIN,
FUNCTION AND STRUCTURAL PROGRESSION: A LONGITUDINAL
STUDY OF PERSONS WITH KNEE OSTEOARTHRITIS
D.L. Riddle, G. Moxley, L. Dumenci. Virginia Commonwealth Univ.,
Richmond, VA, USA
Purpose: Recently published research suggests that statins may have
beneﬁcial structural effects in persons with knee osteoarthritis. The
potential effects of statins on patient-reported knee pain and function
have not been examined. We studied a large prospective community-
based cohort of persons with knee osteoarthritis to determine if statin
usage was associated with changes in knee structure, pain and function
trajectories over a 4-year period.
Methods: Data were obtained from a subset of 2,207 persons in the
Osteoarthritis Initiative with radiographically suspected or conﬁrmed
knee osteoarthritis. The changes in WOMAC Pain and Physical Function
scores, pain intensity and Kellgren-Lawrence radiographic grade over
four years were examined. Data from persons were coded based on
whether they were incident users of statins over the 4-year period.
Statin use duration data also were collected. Outcome trajectories and
probability of statin use were examined over the 4-year study period
using parallel processing growth curve modeling. The analysis adjusted
for potential confounders and determined if statin use predicted
outcome trajectories.
Results: Statin users accounted for 6.7% of the sample in year 1 and
16.4% in year 4. Extent of statin use was not associated with improve-
ments in knee pain, function or structural progression trajectories. The
only signiﬁcant ﬁnding indicated that increased duration of statin use
was associated with worsening in WOMAC Physical Function scores
over the study period (beta¼ 0.161, p¼ 0.005). The Figure illustrates the
full structural equation model for WOMAC Physical Function scores and
statin use over the study period.
Conclusions: Statin use was not associated with improvements in knee
pain, function, or structural progression over the 4-year study period.Ă
574
IMPROVEMENT OF SYMPTOMS IN THE GENERALIZED
OSTEOARTHRITIS USE OF ZOLEDRONIC ACID ZOLA STUDY
L.A. gutierrez, Sr.. Hosp. Univ.rio de Caracas, Caracas, Bolivarian Republic
Of Venezuela
Purpose: In the past it was thought that osteoarthritis (OA) was
a disease of wear, current evidence indicates that the OA is an
inﬂammatory disease signs given by the presence of synovial hyper-
plasia, increased angiogenesis, increased expression of IL-1, TNF, COX-
2 and matrix metalloproteinases (MMP). The activation of chon-
drocytes by mechanical stress, inﬂammatory cytokines, fragments of
collagen and ﬁbronectin, leading to the production of IL-1, TNF-alpha
and PGE2 nitric oxide, which in turn determine the reduction of
proteoglycan synthesis , activation of MMP, peroxynitrate, JNK acti-
vation and apoptosis of chondrocytes which ultimately leads to
cartilage destruction. The cartilage damage leads to increased trans-
mission of forces to the underlying bone due to the decreased elas-
ticity of cartilage, bone microfractures and this produces increased
bone turnover. All these changes occur in the subchondral bone, we
know the holding capacity of bisphosphonates on bone turnover in
2005 presented the results of the BRISK study (Risedronate in OA),
however the dose used was 15mg / d with increased adverse effects
and poor adherence to medication.
Methods: The type of study was a prospective, uncontrolled with
quarterly assessments following the application of zoledronic acid
5mg/100cc semester. The selection of patients was conducted during
October 2009 to December 2011, including 85 patients (n ¼ 85), with
over 50 years and diagnosed with osteoarthritis in three or more joint
groups (distal and proximal interphalangeal, ﬁrst carpometacarpal ,
axial skeleton, hips, knees and metatarsophalangeal). We excluded
patients who were receiving bisphosphonates for 6 months before
recruitment as well as patients with a history of fractures, severe
osteoporosis and joint replacement. We used the WOMAC index that
measures 3
ITEM: Pain, stiffness and physical function, in addition we applied the
visual analog scale (VAS) and asked about the use of NSAIDs and / or
pain in the last days of applying 5-3-2 the questionnaire. We measured
serum CTX-II every 3 months.
Results: Of all patients who entered the study (n ¼ 85): 73.3% (n ¼ 74)
were female and 26.6% (n ¼ 9) male, with a mean (M  SD) of 61.88 
7.33 years, BMI 29.2  58.5 baseline WOMAC Kg/mt2 2.3, 59.1  2.0 3m
WOMAC, WOMAC 6m 47  1.6; measurement baseline VAS 7.5  0.2;
VAS3m 4.2  0.5; VAS6m 2.5  1.2; baseline CTx-II 0,735  0,036 ng /
mol; CTx-II 3m 0.548  0.014 ng / mol; CTx-II 6m 0.233  0.002 ng /
mol.
Conclusions: In this study we observed a substantial improvement
with the use of bisphosphonates in cross section at 6 months was
achieved in addition to reducing the taking of NSAIDs and / or pain after
implementation, the sustained reduction in CTx-Biomarker II remained
even last 3 months of the ﬁrst application. Because the court date is not
radiological control measures were shown to be effective from a struc-
tural standpoint
